nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—ABCB1—melanoma	0.241	1	CbGaD
Ergotamine—CYP1A2—Carmustine—melanoma	0.103	0.227	CbGbCtD
Ergotamine—CYP1A2—Vemurafenib—melanoma	0.0813	0.179	CbGbCtD
Ergotamine—CYP3A4—Temozolomide—melanoma	0.0778	0.172	CbGbCtD
Ergotamine—CYP1A2—Dacarbazine—melanoma	0.0623	0.138	CbGbCtD
Ergotamine—ABCB1—Dactinomycin—melanoma	0.0473	0.104	CbGbCtD
Ergotamine—CYP3A4—Vemurafenib—melanoma	0.0426	0.094	CbGbCtD
Ergotamine—ABCB1—Docetaxel—melanoma	0.0244	0.0538	CbGbCtD
Ergotamine—HTR1D—meninx—melanoma	0.0216	0.388	CbGeAlD
Ergotamine—CYP3A4—Docetaxel—melanoma	0.0146	0.0323	CbGbCtD
Ergotamine—HTR2A—hindlimb—melanoma	0.00255	0.0458	CbGeAlD
Ergotamine—HTR1B—blood vessel—melanoma	0.00254	0.0455	CbGeAlD
Ergotamine—HTR1D—blood vessel—melanoma	0.00246	0.044	CbGeAlD
Ergotamine—HTR2A—appendage—melanoma	0.00219	0.0393	CbGeAlD
Ergotamine—HTR1F—head—melanoma	0.00187	0.0335	CbGeAlD
Ergotamine—HTR1E—head—melanoma	0.00162	0.029	CbGeAlD
Ergotamine—HTR2A—endothelium—melanoma	0.00132	0.0237	CbGeAlD
Ergotamine—HTR1D—eye—melanoma	0.00131	0.0234	CbGeAlD
Ergotamine—HTR2A—blood vessel—melanoma	0.00122	0.0219	CbGeAlD
Ergotamine—HTR2B—skin of body—melanoma	0.00106	0.019	CbGeAlD
Ergotamine—ADRA1B—head—melanoma	0.00101	0.0182	CbGeAlD
Ergotamine—ADRA1D—head—melanoma	0.000992	0.0178	CbGeAlD
Ergotamine—DRD2—eye—melanoma	0.000984	0.0176	CbGeAlD
Ergotamine—DRD2—retina—melanoma	0.000975	0.0175	CbGeAlD
Ergotamine—HTR2A—neck—melanoma	0.000872	0.0156	CbGeAlD
Ergotamine—ABCB1—blood vessel—melanoma	0.000799	0.0143	CbGeAlD
Ergotamine—HTR1B—head—melanoma	0.000766	0.0137	CbGeAlD
Ergotamine—HTR1D—head—melanoma	0.000742	0.0133	CbGeAlD
Ergotamine—HTR2C—head—melanoma	0.000734	0.0132	CbGeAlD
Ergotamine—HTR2B—head—melanoma	0.00069	0.0124	CbGeAlD
Ergotamine—HTR2A—eye—melanoma	0.000649	0.0116	CbGeAlD
Ergotamine—HTR2A—retina—melanoma	0.000643	0.0115	CbGeAlD
Ergotamine—HTR1A—head—melanoma	0.000618	0.0111	CbGeAlD
Ergotamine—SLC6A2—head—melanoma	0.000613	0.011	CbGeAlD
Ergotamine—ADRA2A—mammalian vulva—melanoma	0.000606	0.0109	CbGeAlD
Ergotamine—ADRA1A—head—melanoma	0.00057	0.0102	CbGeAlD
Ergotamine—DRD2—head—melanoma	0.000559	0.01	CbGeAlD
Ergotamine—HTR2B—lymph node—melanoma	0.000483	0.00866	CbGeAlD
Ergotamine—ADRA2A—head—melanoma	0.000433	0.00777	CbGeAlD
Ergotamine—SLC6A2—lymph node—melanoma	0.000429	0.00769	CbGeAlD
Ergotamine—ABCB1—retina—melanoma	0.000421	0.00756	CbGeAlD
Ergotamine—Dihydroergotamine—ABCB1—melanoma	0.000408	0.415	CrCbGaD
Ergotamine—Ergonovine—ABCB1—melanoma	0.000373	0.379	CrCbGaD
Ergotamine—HTR2A—head—melanoma	0.000368	0.0066	CbGeAlD
Ergotamine—ABCB1—mammalian vulva—melanoma	0.000337	0.00605	CbGeAlD
Ergotamine—ADRA2A—lymph node—melanoma	0.000303	0.00544	CbGeAlD
Ergotamine—ABCB1—head—melanoma	0.000241	0.00433	CbGeAlD
Ergotamine—Bromocriptine—ABCB1—melanoma	0.000202	0.206	CrCbGaD
Ergotamine—ABCB1—lymph node—melanoma	0.000169	0.00303	CbGeAlD
Ergotamine—ADRA1A—Signaling Pathways—MDM2—melanoma	6.81e-06	2.73e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MMP9—melanoma	6.81e-06	2.73e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—MAPK1—melanoma	6.79e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—melanoma	6.78e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CDKN1A—melanoma	6.78e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MMP9—melanoma	6.77e-06	2.72e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PRKCA—melanoma	6.77e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PTEN—melanoma	6.77e-06	2.72e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CB—melanoma	6.77e-06	2.72e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—FGF2—melanoma	6.76e-06	2.71e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CDKN1A—melanoma	6.75e-06	2.71e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NFKB1—melanoma	6.74e-06	2.7e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PTEN—melanoma	6.73e-06	2.7e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ERCC2—melanoma	6.72e-06	2.7e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—ERBB2—melanoma	6.71e-06	2.69e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NFKB1—melanoma	6.7e-06	2.69e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CCND1—melanoma	6.68e-06	2.68e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CG—melanoma	6.64e-06	2.67e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK3—melanoma	6.64e-06	2.66e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CB—melanoma	6.63e-06	2.66e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	6.61e-06	2.65e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CXCL8—melanoma	6.61e-06	2.65e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—melanoma	6.6e-06	2.65e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—melanoma	6.57e-06	2.64e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—HRAS—melanoma	6.57e-06	2.64e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CXCL8—melanoma	6.5e-06	2.61e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—melanoma	6.48e-06	2.6e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—HRAS—melanoma	6.46e-06	2.59e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	6.46e-06	2.59e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MYC—melanoma	6.45e-06	2.59e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1B—melanoma	6.45e-06	2.59e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PTEN—melanoma	6.45e-06	2.59e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NFKB1—melanoma	6.41e-06	2.57e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARG—melanoma	6.41e-06	2.57e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—KRAS—melanoma	6.41e-06	2.57e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—PIK3CA—melanoma	6.4e-06	2.57e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—melanoma	6.38e-06	2.56e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CXCL8—melanoma	6.37e-06	2.56e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTEN—melanoma	6.36e-06	2.55e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	6.35e-06	2.55e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1B—melanoma	6.35e-06	2.55e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—melanoma	6.33e-06	2.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MDM2—melanoma	6.33e-06	2.54e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—HRAS—melanoma	6.33e-06	2.54e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CASP3—melanoma	6.33e-06	2.54e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL2—melanoma	6.32e-06	2.54e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MAPK1—melanoma	6.31e-06	2.53e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—melanoma	6.31e-06	2.53e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—melanoma	6.29e-06	2.52e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—melanoma	6.28e-06	2.52e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—melanoma	6.28e-06	2.52e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—STAT3—melanoma	6.27e-06	2.52e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—PIK3CA—melanoma	6.27e-06	2.52e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NRAS—melanoma	6.26e-06	2.51e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—ERBB2—melanoma	6.24e-06	2.5e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CASP3—melanoma	6.22e-06	2.5e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1B—melanoma	6.22e-06	2.5e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL2—melanoma	6.21e-06	2.49e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TP53—melanoma	6.19e-06	2.49e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—melanoma	6.18e-06	2.48e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCND1—melanoma	6.16e-06	2.47e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	6.16e-06	2.47e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—melanoma	6.15e-06	2.47e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—melanoma	6.11e-06	2.45e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CTNNB1—melanoma	6.1e-06	2.45e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CASP3—melanoma	6.09e-06	2.45e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL2—melanoma	6.09e-06	2.44e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—melanoma	6.08e-06	2.44e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TP53—melanoma	6.06e-06	2.43e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCND1—melanoma	6.06e-06	2.43e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—melanoma	6.05e-06	2.43e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—STAT3—melanoma	6.05e-06	2.43e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NRAS—melanoma	6.04e-06	2.42e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—STAT3—melanoma	6.02e-06	2.42e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NRAS—melanoma	6.01e-06	2.41e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CTNNB1—melanoma	6e-06	2.41e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK3—melanoma	5.99e-06	2.4e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—melanoma	5.98e-06	2.4e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—KRAS—melanoma	5.96e-06	2.39e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CDKN1A—melanoma	5.96e-06	2.39e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PTEN—melanoma	5.94e-06	2.39e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCND1—melanoma	5.93e-06	2.38e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—HRAS—melanoma	5.92e-06	2.38e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CXCL8—melanoma	5.92e-06	2.37e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NFKB1—melanoma	5.91e-06	2.37e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—PIK3CA—melanoma	5.89e-06	2.36e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—melanoma	5.88e-06	2.36e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—HRAS—melanoma	5.88e-06	2.36e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	5.87e-06	2.36e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CDKN1A—melanoma	5.86e-06	2.35e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PTEN—melanoma	5.85e-06	2.35e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CD—melanoma	5.84e-06	2.34e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MYC—melanoma	5.83e-06	2.34e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—melanoma	5.82e-06	2.34e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NFKB1—melanoma	5.82e-06	2.34e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—HRAS—melanoma	5.8e-06	2.33e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—melanoma	5.8e-06	2.33e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK3—melanoma	5.78e-06	2.32e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	5.78e-06	2.32e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—melanoma	5.77e-06	2.31e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—STAT3—melanoma	5.76e-06	2.31e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—melanoma	5.76e-06	2.31e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK3—melanoma	5.75e-06	2.31e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NRAS—melanoma	5.75e-06	2.31e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	5.74e-06	2.3e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PTEN—melanoma	5.73e-06	2.3e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	5.72e-06	2.29e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—melanoma	5.7e-06	2.29e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MAPK1—melanoma	5.7e-06	2.29e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—melanoma	5.7e-06	2.29e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NFKB1—melanoma	5.7e-06	2.29e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TP53—melanoma	5.7e-06	2.29e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ABCB1—melanoma	5.68e-06	2.28e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—melanoma	5.67e-06	2.28e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CASP3—melanoma	5.66e-06	2.27e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL2—melanoma	5.65e-06	2.27e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—melanoma	5.63e-06	2.26e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MYC—melanoma	5.62e-06	2.26e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MYC—melanoma	5.6e-06	2.25e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—melanoma	5.59e-06	2.24e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.56e-06	2.23e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—melanoma	5.55e-06	2.23e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCND1—melanoma	5.51e-06	2.21e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK3—melanoma	5.51e-06	2.21e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MAPK1—melanoma	5.5e-06	2.21e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—melanoma	5.5e-06	2.21e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—PIK3CA—melanoma	5.48e-06	2.2e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MAPK1—melanoma	5.47e-06	2.2e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—melanoma	5.47e-06	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	5.46e-06	2.19e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—HRAS—melanoma	5.45e-06	2.19e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—KRAS—melanoma	5.38e-06	2.16e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—melanoma	5.37e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MYC—melanoma	5.36e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—melanoma	5.35e-06	2.15e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	5.33e-06	2.14e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PTEN—melanoma	5.32e-06	2.14e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—STAT3—melanoma	5.31e-06	2.13e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CG—melanoma	5.3e-06	2.13e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NRAS—melanoma	5.3e-06	2.13e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TP53—melanoma	5.3e-06	2.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NFKB1—melanoma	5.29e-06	2.13e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—melanoma	5.28e-06	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MAPK1—melanoma	5.24e-06	2.1e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—melanoma	5.24e-06	2.1e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—STAT3—melanoma	5.23e-06	2.1e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—melanoma	5.23e-06	2.1e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PRKCA—melanoma	5.23e-06	2.1e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NRAS—melanoma	5.22e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—melanoma	5.21e-06	2.09e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—KRAS—melanoma	5.2e-06	2.09e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—melanoma	5.19e-06	2.08e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ERCC2—melanoma	5.18e-06	2.08e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—melanoma	5.17e-06	2.08e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—KRAS—melanoma	5.17e-06	2.08e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—melanoma	5.12e-06	2.06e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—STAT3—melanoma	5.12e-06	2.06e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARG—melanoma	5.12e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NRAS—melanoma	5.11e-06	2.05e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CB—melanoma	5.09e-06	2.04e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK3—melanoma	5.08e-06	2.04e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—HRAS—melanoma	5.07e-06	2.03e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—melanoma	5.04e-06	2.02e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK3—melanoma	5e-06	2.01e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—KRAS—melanoma	4.95e-06	1.99e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	4.95e-06	1.99e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MYC—melanoma	4.94e-06	1.98e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK3—melanoma	4.89e-06	1.96e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MYC—melanoma	4.86e-06	1.95e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—melanoma	4.85e-06	1.95e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MAPK1—melanoma	4.83e-06	1.94e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—melanoma	4.83e-06	1.94e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—melanoma	4.81e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—melanoma	4.81e-06	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TP53—melanoma	4.79e-06	1.92e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—PIK3CA—melanoma	4.77e-06	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MYC—melanoma	4.76e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—STAT3—melanoma	4.76e-06	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MAPK1—melanoma	4.75e-06	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—melanoma	4.75e-06	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—PIK3CA—melanoma	4.75e-06	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NRAS—melanoma	4.75e-06	1.91e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CD—melanoma	4.66e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MAPK1—melanoma	4.65e-06	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—melanoma	4.65e-06	1.87e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TP53—melanoma	4.62e-06	1.85e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—melanoma	4.6e-06	1.85e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TP53—melanoma	4.6e-06	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—HRAS—melanoma	4.58e-06	1.84e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—KRAS—melanoma	4.56e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	4.55e-06	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK3—melanoma	4.55e-06	1.82e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—KRAS—melanoma	4.49e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3CA—melanoma	4.49e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—melanoma	4.48e-06	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MYC—melanoma	4.42e-06	1.77e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—HRAS—melanoma	4.42e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTEN—melanoma	4.4e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TP53—melanoma	4.4e-06	1.77e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—KRAS—melanoma	4.4e-06	1.76e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—HRAS—melanoma	4.4e-06	1.76e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—melanoma	4.38e-06	1.76e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MAPK1—melanoma	4.32e-06	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—melanoma	4.32e-06	1.74e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—melanoma	4.23e-06	1.7e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—HRAS—melanoma	4.21e-06	1.69e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—melanoma	4.21e-06	1.69e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3CA—melanoma	4.19e-06	1.68e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3CA—melanoma	4.13e-06	1.66e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CG—melanoma	4.09e-06	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—KRAS—melanoma	4.08e-06	1.64e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CB—melanoma	4.06e-06	1.63e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TP53—melanoma	4.06e-06	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—melanoma	4.04e-06	1.62e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	4.04e-06	1.62e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—melanoma	4.03e-06	1.62e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—melanoma	4.03e-06	1.62e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TP53—melanoma	3.99e-06	1.6e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARG—melanoma	3.95e-06	1.59e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TP53—melanoma	3.91e-06	1.57e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—melanoma	3.9e-06	1.57e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—melanoma	3.88e-06	1.56e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—HRAS—melanoma	3.88e-06	1.56e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—HRAS—melanoma	3.82e-06	1.53e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	3.75e-06	1.51e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—HRAS—melanoma	3.74e-06	1.5e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—melanoma	3.71e-06	1.49e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—melanoma	3.71e-06	1.49e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—melanoma	3.67e-06	1.47e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—melanoma	3.65e-06	1.47e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TP53—melanoma	3.63e-06	1.46e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CD—melanoma	3.6e-06	1.44e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—melanoma	3.58e-06	1.44e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—melanoma	3.55e-06	1.43e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTEN—melanoma	3.51e-06	1.41e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—HRAS—melanoma	3.47e-06	1.39e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—melanoma	3.42e-06	1.37e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—melanoma	3.37e-06	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—melanoma	3.32e-06	1.33e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—melanoma	3.3e-06	1.32e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CB—melanoma	3.14e-06	1.26e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—melanoma	3.11e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3CA—melanoma	3.1e-06	1.25e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—melanoma	3.07e-06	1.23e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTEN—melanoma	2.71e-06	1.09e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—melanoma	2.54e-06	1.02e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3CA—melanoma	2.48e-06	9.94e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—melanoma	2.02e-06	8.12e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3CA—melanoma	1.91e-06	7.68e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—melanoma	1.56e-06	6.27e-06	CbGpPWpGaD
